These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 14506185

  • 1. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.
    Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, Skarnemark G.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3873S-9S. PubMed ID: 14506185
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule.
    Frost SH, Jensen H, Lindegren S.
    Cancer; 2010 Feb 15; 116(4 Suppl):1101-10. PubMed ID: 20127953
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.
    Lindegren S, Andersson H, Jacobsson L, Bäck T, Skarnemark G, Karlsson B.
    Bioconjug Chem; 2002 Feb 15; 13(3):502-9. PubMed ID: 12009939
    [Abstract] [Full Text] [Related]

  • 4. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
    Frost SH, Bäck T, Chouin N, Jensen H, Hultborn R, Jacobsson L, Lindegren S.
    Cancer Biother Radiopharm; 2011 Dec 15; 26(6):727-36. PubMed ID: 22087606
    [Abstract] [Full Text] [Related]

  • 5. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
    Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, Palm S.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
    [Abstract] [Full Text] [Related]

  • 6. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA, Meares CF, Osen M.
    J Nucl Med; 1998 Oct 01; 39(10):1813-8. PubMed ID: 9776294
    [Abstract] [Full Text] [Related]

  • 7. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.
    Nucl Med Biol; 2005 Oct 01; 32(7):741-7. PubMed ID: 16243650
    [Abstract] [Full Text] [Related]

  • 8. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [Abstract] [Full Text] [Related]

  • 9. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, Corstens FH, Boerman OC.
    J Nucl Med; 2005 Jun 01; 46(6):1016-22. PubMed ID: 15937314
    [Abstract] [Full Text] [Related]

  • 10. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
    Lindegren S, Frost S, Bäck T, Haglund E, Elgqvist J, Jensen H.
    J Nucl Med; 2008 Sep 01; 49(9):1537-45. PubMed ID: 18703591
    [Abstract] [Full Text] [Related]

  • 11. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [Abstract] [Full Text] [Related]

  • 12. Pretargeted radioimmunotherapy.
    Meredith RF, Buchsbaum DJ.
    Int J Radiat Oncol Biol Phys; 2006 Sep 01; 66(2 Suppl):S57-9. PubMed ID: 16979441
    [Abstract] [Full Text] [Related]

  • 13. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
    Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS.
    Bioconjug Chem; 2005 Sep 01; 16(1):131-8. PubMed ID: 15656584
    [Abstract] [Full Text] [Related]

  • 14. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 01; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 15. Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.
    Hainsworth J, Harrison P, Mather SJ.
    Bioconjug Chem; 2005 Jul 01; 16(6):1468-74. PubMed ID: 16287243
    [Abstract] [Full Text] [Related]

  • 16. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8180-5. PubMed ID: 16299250
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 15; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

  • 18. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH.
    J Nucl Med; 2003 Mar 15; 44(3):400-11. PubMed ID: 12621007
    [Abstract] [Full Text] [Related]

  • 19. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.
    J Nucl Med; 2005 Apr 15; 46(4):642-51. PubMed ID: 15809487
    [Abstract] [Full Text] [Related]

  • 20. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec 15; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.